Thursday, October 22, 2026
ExploreSearch
Via News

Tech Sector Growth

2 articles

NVIDIA BioNeMo Platform Secures Lilly and Thermo Fisher as AI Drug Discovery Partners

NVIDIA BioNeMo Platform Secures Lilly and Thermo Fisher as AI Drug Discovery Partners

NVIDIA has positioned its BioNeMo platform as core infrastructure for biotech AI, securing partnerships with pharmaceutical giants Eli Lilly and Thermo Fisher Scientific.<sup>1</sup> The platform enables biotech startups including Terray, Apheris, Natera, and Basecamp Research to build foundation models for drug discovery. This expansion mirrors NVIDIA's GPU dominance strategy in a vertical market with substantial R&D budgets.

LM Salvado•
Robotics Sector Hits Commercial Scale as Warehouse Automation Reaches 98% Accuracy

Robotics Sector Hits Commercial Scale as Warehouse Automation Reaches 98% Accuracy

The robotics industry is transitioning from R&D to commercial deployment across manufacturing, logistics, and defense sectors. AI-powered warehouse systems now achieve 98%+ accuracy rates, while autonomous vehicle production timelines target 2026-2027 launches. The convergence of AI breakthroughs and 5G infrastructure is creating investment opportunities in equipment manufacturers and automation software.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com